- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05887895
To Compare the Pharmacokinetics and Pharmacodynamics of HR20014, INS068 and INS062 After Single Subcutaneous Injection in Healthy Subjects
A Trial Comparing the Pharmacodynamics and Pharmacokinetics of HR20014, INS068 and INS062 in Healthy Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Anhui
-
Hefei, Anhui, China, 230601
- The Second Affiliated Hospital of Anhui Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Able and willing to provide a written informed consent;
- Male or female aged 18-45 at screening (both inclusive);
- Subjects who are considered to be generally healthy, based on an assessment of medical history, physical examination and clinical laboratory data, as judged by the Investigator;
- Male weight ≥ 50.0 kg, female weight ≥ 45.0 kg, body mass index (BMI) in 18.0~26.0 kg/m2 (both inclusive);
- During the screening phase oral glucose tolerance test (OGTT), intravenous fasting plasma glucose ≥3.9 mmol/L and < 6.1 mmol/L; Glucose 2 hours after negative charge static pulse blood sugar <7.8mmol/L; and normal or abnormal insulin levels have no clinical significance.
Exclusion Criteria:
- A history of recurrent or severe drug food allergy, or known or suspected allergy to any component of the study drug;
- Have a history of hypertension;
- Severe systemic infectious diseases within 1 month before screening;
- Patients with a history of lower extremity deep vein thrombosis or high risk of lower extremity deep vein thrombosis;
- Patients with serious diseases of the psychiatric, cardiovascular, respiratory, digestive, endocrine, blood, urogenital and other systems in the past, or existing diseases of the above systems, were judged by the researchers to be unfit to participate in this study;
- Use of prescription drugs (topical eye/nasal drops and creams and occasional antipyretic and analgesic drugs such as acetaminophen within recommended doses are permitted) and over-the-counter drugs, and Chinese herbal medicine (regular vitamins are allowed) within 2 weeks before screening;
- Presence of any abnormal and clinically significant laboratory tests.
- ECG (12-lead electrocardiogram) showed abnormal and clinically significant.
- Those who have participated in any drug clinical trials within 3 months or 5 half-life periods before screening (the elder shall prevail), who participated in clinical trials are defined as random, prior to screening.
- Blood donation within 1 month before screening; Or patients with trauma or major surgical procedures who donated blood or lost blood ≥400 mL in the 3 months prior to screening.
- Women who are pregnant, breastfeeding or planning to conceive, or women of childbearing potential (WOCBP) are reluctant to use appropriate contraception during the trial.
- The investigators determined that other conditions were inappropriate for participation in this clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment group sequence 1
Subjects were given HR20014, INS068, or INS062 injections subcutaneously once in three cycles.
The interval of each dosing visit was 7 to 21 days.
|
INS062 injection:A single dose of 0.4 DU/kg is administered to healthy subjects. INS068 injection:A single dose of 0.4 U/kg is administered to healthy subjects. HR20014 injection:A single dose of 0.4 U/kg is administered to healthy subjects. |
Experimental: Treatment group sequence 2
Subjects were given HR20014, INS062, or INS068 injections subcutaneously once in three cycles.
The interval of each dosing visit was 7 to 21 days.
|
INS062 injection:A single dose of 0.4 DU/kg is administered to healthy subjects. INS068 injection:A single dose of 0.4 U/kg is administered to healthy subjects. HR20014 injection:A single dose of 0.4 U/kg is administered to healthy subjects. |
Experimental: Treatment group sequence 3
Subjects were given INS068, HR20014, or INS062 injections subcutaneously once in three cycles.
The interval of each dosing visit was 7 to 21 days.
|
INS062 injection:A single dose of 0.4 DU/kg is administered to healthy subjects. INS068 injection:A single dose of 0.4 U/kg is administered to healthy subjects. HR20014 injection:A single dose of 0.4 U/kg is administered to healthy subjects. |
Experimental: Treatment group sequence 4
Subjects were given INS068, INS062, or HR20014 injections subcutaneously once in three cycles.
The interval of each dosing visit was 7 to 21 days.
|
INS062 injection:A single dose of 0.4 DU/kg is administered to healthy subjects. INS068 injection:A single dose of 0.4 U/kg is administered to healthy subjects. HR20014 injection:A single dose of 0.4 U/kg is administered to healthy subjects. |
Experimental: Treatment group sequence 5
Subjects were given INS062, HR20014, or INS068 injections subcutaneously once in three cycles.
The interval of each dosing visit was 7 to 21 days.
|
INS062 injection:A single dose of 0.4 DU/kg is administered to healthy subjects. INS068 injection:A single dose of 0.4 U/kg is administered to healthy subjects. HR20014 injection:A single dose of 0.4 U/kg is administered to healthy subjects. |
Experimental: Treatment group sequence 6
Subjects were given INS062, INS068, or HR20014 injections subcutaneously once in three cycles.
The interval of each dosing visit was 7 to 21 days.
|
INS062 injection:A single dose of 0.4 DU/kg is administered to healthy subjects. INS068 injection:A single dose of 0.4 U/kg is administered to healthy subjects. HR20014 injection:A single dose of 0.4 U/kg is administered to healthy subjects. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the Glucose Infusion Rate (GIR) - time curve (Only for HR20014 and INS068)
Time Frame: 0 hour to 6 hours after dosing
|
0 hour to 6 hours after dosing
|
Area under the Glucose Infusion Rate (GIR) - time curve (Only for HR20014 and INS062)
Time Frame: 6 hours to 24 hours after dosing
|
6 hours to 24 hours after dosing
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the Glucose Infusion Rate (GIR) - time curve
Time Frame: 0 hour to 96 hours after dosing
|
Based on the absolute dose and concentration of INS068
|
0 hour to 96 hours after dosing
|
Maximum concentration of INS068
Time Frame: 0 hour to 96 hours after dosing
|
Based on the absolute dose and concentration of INS068
|
0 hour to 96 hours after dosing
|
Area under the Glucose Infusion Rate (GIR) - time curve
Time Frame: 0 hour to 10 hours after dosing
|
Based on the absolute dose and concentration of INS062
|
0 hour to 10 hours after dosing
|
Maximum concentration of INS062
Time Frame: 0 hour to 10 hours after dosing
|
Based on the absolute dose and concentration of INS062
|
0 hour to 10 hours after dosing
|
Incidence and severity of adverse events (AEs)
Time Frame: from screening to 7-21 days after the last dosing
|
from screening to 7-21 days after the last dosing
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- HR20014-102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
Taichung Veterans General HospitalNational Health Research Institutes, TaiwanRecruitingDiabetes Complications | Type 2 Diabetes | Maturity-Onset Diabetes of the Young (MODY)Taiwan
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
Oregon State UniversitySanofiCompletedType I or Type II Diabetes (Excludes Gestational Diabetes)
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
University of RoehamptonRecruitingType2 Diabetes Mellitus | Pre DiabetesUnited Kingdom
Clinical Trials on INS062 injection、INS068 injection、HR20014 injection
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruiting
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
Jiangsu HengRui Medicine Co., Ltd.Active, not recruiting
-
Jiangsu HengRui Medicine Co., Ltd.CompletedType 2 DiabetesAustralia, China, United States
-
National Taiwan University HospitalRecruitingOsteoarthritis (OA) of the KneeTaiwan
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruiting
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Enrolling by invitationAdvanced Malignant TumorsChina